

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

April 2025

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white wavy lines on a grey background.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 April 2025.....	3
Section H changes to Part II	10
Index.....	24

Summary of decisions

EFFECTIVE 1 APRIL 2025

- Acetazolamide (Medsurge) tab 250 mg – new listing and addition of PSS
- Acetazolamide (Diamox) tab 250 mg – to be delisted on 1 September 2025
- Acetylcysteine (Hikma Acetylcysteine) inj 200 mg per ml, 10 ml vial – new listing
- Amino acid formula (without phenylalanine) (PKU Anamix Junior LQ (Berry) and (Orange)) liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle and (PKU Start) powder (neutral), 14.3 g protein, 25 g fat per 100 g, 4 x 400 g can, 1,600 g – new listing
- Amino acid formula (without phenylalanine) (PKU Anamix Junior LQ (Berry) and (Orange)) liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle, 125 ml and (PKU Start) powder (neutral), 14.3 g protein, 25 g fat per 100 g, 400 g can – delisted 1 April 2025
- Amino acid oral feed (Vivonex TEN) powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet, 80 g sachet, 1 sachet – new listing
- Amino acid oral feed (Vivonex TEN) powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet, 80 g – delisted 1 April 2025
- Axitinib (Intyla) tab 1 mg and 5 mg – new listing
- Bevacizumab (Vegzelma) inj 25 mg per ml, 4 ml vial and 16 ml vial – amended restriction criteria
- Bupivacaine hydrochloride (Marcain) inj 2.5 mg per ml, 100 ml bag – to be delisted 1 November 2025
- Calcium folinate (Eurofolic) inj 10 mg per ml, 5 ml vial and 10 ml vial – new listings
- Calcium folinate (Eurofolic) inj 10 mg per ml, 100 ml vial – price increase
- Calcium folinate inj 10 mg per ml, 5 ml ampoule (Calcium Folate Ebewe), 5 ml vial (Calcium Folate Sandoz), 10 ml vial (Calcium Folate Sandoz) and 100 ml vial (Calcium Folate Sandoz) – to be delisted 1 November 2025
- Calcium folinate inj 10 mg per ml, 30 ml vial (Calcium Folate Ebewe) and 35 ml vial (Calcium Folate Sandoz) – brand only to be delisted 1 November 2025
- Calcitriol (Calcitriol XL) cap 0.25 mcg (p'code 2695154) and 0.5 mcg (p'code 2691663) – amended brand name
- Ceftazidime with avibactam (Zavicefta) inj ceftazidime 2,000 mg with avibactam 500 mg, vial – new listing
- Cetomacrogol with glycerol (Evara) crm 90% with glycerol 10%, 460 g and 920 g – new listing
- Cetomacrogol with glycerol (Evara) crm 90% with glycerol 10%, 500 ml and 1,000 ml – delisted 1 April 2025
- Colistin sulphmethate [colestimethate] (Colistin-Link) inj 150 mg per ml, 1 ml vial – to be delisted 1 June 2025

Summary of decisions – effective 1 April 2025 (continued)

- Compound electrolytes with glucose [dextrose] (Hydralyte - Lemonade) soln with electrolytes, 1 L – new listing
- Compound electrolytes with glucose [dextrose] (Hydralyte - Lemonade) soln with electrolytes, 1,000 ml – delisted 1 April 2025
- Crizotinib (Xalkori) cap 200 mg and 250 mg – new listing
- Desmopressin acetate (Desmopressin-PH&T) nasal spray 10 mcg per dose, 6 ml, 60 actuations – new listing
- Desmopressin acetate (Desmopressin-PH&T) nasal spray 10 mcg per dose, 6 ml – delisted 1 April 2025
- Diabetic oral feed 1 kcal/ml (Diasip (strawberry) and Diasip (vanilla)) liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle, 1 bottle – new listing
- Diabetic oral feed 1 kcal/ml (Diasip (strawberry) and Diasip (vanilla)) liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml – delisted 1 April 2025
- Diclofenac sodium (Voltaren SR) tab long-acting 75 mg – price decrease and addition of PSS
- Dimethicone (healthE Dimethicone 5%) crm 5% pump bottle, 460 g and (healthE Dimethicone 10%) crm 10% pump bottle, 460 g – new listing
- Dimethicone (healthE Dimethicone 5%) crm 5% pump bottle, 500 ml and (healthE Dimethicone 10%) crm 10% pump bottle, 500 ml – delisted 1 April 2025
- Desogestrel (Cerazette) tab 75 mcg – new listing
- Elexacaftor with tezacaftor, ivacaftor and ivacaftor (Trikafta) tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg (56) and ivacaftor 75 mg (28) and tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg (56) and ivacaftor 150 mg (28) – amended restriction criteria
- Enteral feed 1 kcal/ml (Nutrison RTH) liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bottle, 1 bottle; (Nutrison Multi Fibre) liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle, 1 bottle; (Osmolite RTH) liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, 1,000 ml bottle, 1 bottle; (Jevity RTH) liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, 1,000 ml bottle, 1 bottle – new listing
- Enteral feed 1 kcal/ml (Nutrison RTH) liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, bottle, 1,000 ml; Nutrison Multi Fibre liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, bottle, 1,000 ml; Osmolite RTH liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle, 1,000 ml; Jevity RTH liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle, 1,000 ml – delisted 1 April 2025

Summary of decisions – effective 1 April 2025 (continued)

- Enteral feed 1.2 kcal/ml (Jevity Plus RTH) liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bottle, 1 bottle – new listing
 - Enteral feed 1.2 kcal/ml (Jevity Plus RTH) liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag, 1,000 ml – delisted 1 April 2025
 - Enteral feed 1.5 kcal/ml (Nutrison Energy) liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, 1,000 ml bottle, 1 bottle; (Nutrison Energy Multi Fibre) liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle, 1 bottle; (Ensure Plus HN) liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, 250 ml can, 1 bottle; (Ensure Plus HN RTH) liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bag, 1 bottle and (Jevity HiCal RTH) liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, 1,000 ml bag, 1 bottle – new listing
 - Enteral feed 1.5 kcal/ml (Nutrison Energy) liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bottle, 1,000 ml; (Nutrison Energy Multi Fibre) liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, bottle, 1,000 ml; (Ensure Plus HN) liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can, 250 ml; (Ensure Plus HN RTH) liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag, 1,000 ml and (Jevity HiCal RTH) liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag, 1,000 ml – delisted 1 April 2025
 - Enteral feed 2 kcal/ml (Nutrison Concentrated) liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 500 ml bottle, 1 bottle and (Ensure Two Cal HN RTH) liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, 1,000 ml bottle, 1 bottle – new listing
 - Enteral feed 2 kcal/ml (Nutrison Concentrated) liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle, 500 ml and (Ensure Two Cal HN RTH) liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle, 1,000 ml – delisted 1 April 2025
 - Enteral feed with fibre 0.83 kcal/ml (Nutrison 800 Complete Multi Fibre) liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle, 1 bottle – new listing
 - Enteral feed with fibre 0.83 kcal/ml (Nutrison 800 Complete Multi Fibre) liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, bottle, 1,000 ml – delisted 1 April 2025
 - Enteral liquid peptide formula (Nutrini Peptisorb Energy) liquid 4.2 g protein, 18.6 g carbohydrate and 6.58 g fat per 100 ml, 500 ml bottle, 1 bottle – new listing
 - Enteral liquid peptide formula (Nutrini Peptisorb Energy) liquid 4.2 g protein, 18.6 g carbohydrate and 6.58 g fat per 100 ml, 500 ml – delisted 1 April 2025
 - Gadobutrol (Gadovist 1.0) inj 604.72 mg per ml (equivalent 1 mmol per ml), 65 ml bottle – new listing
 - Inotuzumab ozogamicin (Besponsa) inj 1 mg vial – new listing
-

Summary of decisions – effective 1 April 2025 (continued)

- Ipilimumab (Yervoy) inj 5 mg per ml, 10 ml vial and 40 ml vial – new listing
- Lanreotide (Mytolac) inj 90 mg per 0.5 ml, 0.5 ml syringe – new listing
- Levonorgestrel (Jadelle) subdermal implant (2 × 75 mg rods), 2 subdermal implants pack – new listing
- Levonorgestrel (Jadelle) subdermal implant (2 × 75 mg rods), 1 original pack – delisted 1 April 2025
- Low electrolyte oral feed 1.8 kcal/ml (Nepro HP (Strawberry) and (Vanilla)) liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, 220 ml carton, 1 carton – new listing
- Low electrolyte oral feed 1.8 kcal/ml (Nepro HP (Strawberry) and (Vanilla)) liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton, 220 ml – delisted 1 April 2025
- Low-GI enteral feed 1 kcal/ml (Glucerna Select) liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 500 ml bottle, 1 bottle – new listing
- Low-GI enteral feed 1 kcal/ml (Glucerna Select) liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 500 ml bottle, 500 ml – delisted 1 April 2025
- Low-GI oral feed 1 kcal/ml (Nutren Diabetes (vanilla)) liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 200 ml bottle, 1 bottle – new listing
- Low-GI oral feed 1 kcal/ml (Nutren Diabetes (Vanilla)) liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 200 ml bottle, 200 ml – delisted 1 April 2025
- Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride (APO Health Macrogol) powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – new listing
- Methylphenidate hydrochloride tab extended-release 18 mg, 27 mg, 36 mg and 54 mg (Concerta and Methylphenidate ER - Teva), tab immediate-release 5 mg, 10 mg and 20 mg (Rubifen), tab immediate-release 10 mg (Ritalin), tab sustained-release 20 mg (Rubifen SR) and cap modified-release 10 mg, 20 mg, 30 mg and 40 mg (Ritalin LA) – amended restriction criteria
- Modafinil (Modafinil Max Health and Modavigil) tab 100 mg – amended restriction criteria
- Nivolumab (Opdivo) inj 10 mg per ml, 4 ml vial and 10 ml vial – amended restriction criteria

Summary of decisions – effective 1 April 2025 (continued)

- Oral feed 1.5 kcal/ml (Ensure Plus (Vanilla)) liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, 237 ml can, 1 can; (Fortisip (banana), (chocolate), (strawberry) and (vanilla)) liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle, 1 bottle and (Ensure Plus (Banana), (Chocolate), (Fruit of the Forest) and (Vanilla)) liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, 200 ml bottle, 1 bottle – new listing
- Oral feed 1.5 kcal/ml (Ensure Plus (Vanilla)) liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can, 237 ml; (Fortisip (banana), (chocolate), (strawberry) and (vanilla)) liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle, 200 ml and (Ensure Plus (Banana), (Chocolate), (Fruit of the Forest) and (Vanilla)) liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, bottle, 200 ml – delisted 1 April 2025
- Oral feed 2 kcal/ml (Two Cal HN) liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, 200 ml bottle, 1 bottle – new listing
- Oral feed 2 kcal/ml (Two Cal HN) liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle, 200 ml – delisted 1 April 2025
- Oral feed with fibre 1.5 kcal/ml (Fortisip Multi Fibre (chocolate), (strawberry) and (vanilla)) liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle, 1 bottle – new listing
- Oral feed with fibre 1.5 kcal/ml (Fortisip Multi Fibre (chocolate), (strawberry) and (vanilla)) liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle, 200 ml – delisted 1 April 2025
- Paediatric enteral feed 0.76 kcal/ml (Nutrini Low Energy Multifibre RTH) liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, 500 ml bottle, 1 bottle – new listing
- Paediatric enteral feed 0.76 kcal/ml (Nutrini Low Energy Multifibre RTH) liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag, 500 ml – delisted 1 April 2025
- Paediatric enteral feed 1 kcal/ml (Nutrini RTH) liquid 2.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bottle and (Pediasure RTH) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 500 ml bottle – new listing
- Paediatric enteral feed 1 kcal/ml (Nutrini RTH) liquid 2.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, bottle, 500 ml and (Pediasure RTH) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag, 500 ml – delisted 1 April 2025
- Paediatric enteral feed 1.5 kcal/ml (Nutrini Energy RTH) liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bottle, 1 bottle and (Nutrini Energy Multi Fibre) liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, 500 ml bottle, 1 bottle – new listing

Summary of decisions – effective 1 April 2025 (continued)

- Paediatric enteral feed 1.5 kcal/ml (Nutrini Energy RTH) liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bottle and (Nutrini Energy Multi Fibre) liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, 500 ml bottle – delisted 1 April 2025
 - Paediatric oral/enteral feed 1 kcal/ml (Infatrini) liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, 125 ml bottle, 1 bottle – new listing
 - Paediatric oral/enteral feed 1 kcal/ml (Infatrini) liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, bottle, 125 ml – delisted 1 April 2025
 - Paediatric oral feed 1 kcal/ml (Pediasure (chocolate), (strawberry) and (vanilla)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 200 ml bottle, 1 bottle and (Pediasure (vanilla)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 250 ml can, 1 bottle – new listing
 - Paediatric oral feed 1 kcal/ml (Pediasure (Chocolate), (Strawberry) and (Vanilla)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bottle, 200 ml and (Pediasure (Vanilla)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, can, 250 ml – delisted 1 April 2025
 - Paediatric oral feed 1.5 kcal/ml (Fortini (Strawberry) and (Vanilla)) liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle, 1 bottle; (Fortini Multi Fibre (chocolate), (strawberry), (unflavoured) and (vanilla)) liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle, 1 bottle and (Pediasure Plus) liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle, 1 bottle – new listing
 - Paediatric oral feed 1.5 kcal/ml (Fortini (Strawberry) and (Vanilla)) liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, bottle, 200 ml; (Fortini Multi Fibre (Chocolate), (Strawberry), (Unflavoured) and (Vanilla)) liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, bottle, 200 ml and (Pediasure Plus) liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle, 500 ml – delisted 1 April 2025
 - Peptide-based enteral feed 1 kcal/ml (Nutrison Advanced Peptisorb) liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, 500 ml bottle, 1 bottle – new listing
 - Peptide-based enteral feed 1 kcal/ml (Nutrison Advanced Peptisorb) liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, bottle, 500 ml – delisted 1 April 2025
 - Peptide-based enteral feed 1.5 kcal/ml (Vital) liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, 1,000 ml bottle, 1 bottle – new listing
 - Peptide-based enteral feed 1.5 kcal/ml (Vital) liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle, 1,000 ml – delisted 1 April 2025
 - Quetiapine (Quetiapine Viatris) tab 25 mg, 30 tab and 500 tab – new listing
-

Summary of decisions – effective 1 April 2025 (continued)

- Rotavirus oral vaccine (Rotarix) oral susp live attenuated human rotavirus 1,000,00 CCID50 per dose, squeezable tube (PVC free) – new listing
- Ribociclib (Kisqali) tab 200 mg, 21 pack (p'code 2701340), 42 pack (p'code 2701359) and 63 pack (p'code 2701367) – new Pharmacode listings
- Ribociclib (Kisqali) tab 200 mg, 21 pack (p'code 2678772), 42 pack (p'code 2678780) and 63 pack (p'code 2678799) – to be delisted 1 December 2025
- Sunitinib (Sunitinib Pfizer) cap 12.5 mg, 25 mg and 50 mg – amended restriction criteria
- Tacrolimus (Tacrolimus Sandoz) cap 0.5 mg, 0.75 mg, 1 mg and 5 mg and inj 5 mg per ml, 1 ml ampoule – amended restriction criteria
- Testosterone (Testogel) gel (transdermal) 16.2 mg per g, 88 g, 60 actuations – new listing
- Testosterone (Testogel) gel (transdermal) 16.2 mg per g, 88 g – delisted 1 April 2025
- Thiamine hydrochloride inj 125 mg per ml, 2 ml vial – new listing
- Varenicline (Champix) tab 0.5 mg × 11 and 1 mg × 42 and tab 1 mg – new listing
- Varenicline (Varenicline Pfizer) tab 0.5 mg × 11 and 1 mg × 42 and tab 1 mg – delisted 1 April 2025
- Ursodeoxycholic acid (Urosan) cap 250 mg – amended restriction criteria
- Zoledronic acid (Zoledronic Acid Viatri) inj 5 mg per 100 ml, 100 ml bag – new listing
- Zoledronic acid (Zoledronic Acid Viatri) inj 5 mg per 100 ml, bag, 100 ml – delisted 1 April 2025

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 April 2025

ALIMENTARY TRACT AND METABOLISM

13	URSODEOXYCHOLIC ACID (amended restriction criteria – affected criteria shown only) → Cap 250 mg – 5% DV Feb-24 to 2026	33.95	100	Ursosan
	Restricted Initiation – prevention of sinusoidal obstruction syndrome <i>Limited to 6 months treatment</i> Both: 1 – The patient is enrolled in the Children’s Oncology Group AALL1732 trial; and 2 – The patient has leukaemia/lymphoma and is receiving inotuzumab-ozogamicin. The individual has leukaemia/lymphoma and requires prophylaxis for medications/therapies with a high risk of sinusoidal obstruction syndrome.			
15	MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE (new listing) Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg	8.50	30	APO Health Macrogol
28	CALCITRIOL (amended brand name) Cap 0.25 mcg..... Cap 0.5 mcg.....	7.89 13.68	100 100	Calcitriol XL AFT Calcitriol XL AFT
	Note – this brand name amendment only applies to Pharmacodes 2695154 and 2691663.			
28	THIAMINE HYDROCHLORIDE (new listing) Inj 125 mg per ml, 2 ml vial			

BLOOD AND BLOOD FORMING ORGANS

42	COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] (new listing and delisted) Soln with electrolytes – 5% DV Apr-25 to 2025	6.53	1	Hydralyte – Lemonade
	Note – Hydralyte – Lemonade soln with electrolytes, 1,000 ml delisted 1 April 2025.			

DERMATOLOGICALS

69	DIMETHICONE (new listing and delisted) Crm 5% pump bottle – 5% DV Apr-25 to 2025 Crm 10% pump bottle.....	4.30 4.52	460 g 460 g	healthE Dimethicone 5% healthE Dimethicone 10%
	Note – healthE Dimethicone 5% crm 5% pump bottle, 500 ml and healthE Dimethicone 10% crm 10% pump bottle, 500 ml delisted 1 April 2025.			
70	CETOMACROGOL WITH GLYCEROL (new listing and delisted) Crm 90% with glycerol 10% – 5% DV Apr-25 to 2025	2.13 3.50	460 g 920 g	Evara Evara
	Note: DV limit applies to the pack sizes of greater than 100 g. Note – Evara crm 90% with glycerol 10%, 500 ml and 1,000 ml delisted 1 April 2025.			

GENITO-URINARY SYSTEM

76	DESOGESTREL (new listing) Tab 75 mcg.....	24.50	84	Cerazette
----	--	-------	----	-----------

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

76	LEVONORGESTREL (new listing and delisted) Subdermal implant (2 × 75 mg rods) – 5% DV Apr-25 to 2026	106.92	2	Jadelle
Note – Jadelle subdermal implant (2 × 75 mg rods), 1 pack delisted 1 April 2025.				

HORMONE PREPARATIONS

79	TESTOSTERONE (new listing and delisted) Gel (transdermal) 16.2 mg per g, 88 g – 5% DV Apr-25 to 2027	52.00	60	Testogel
Note – Testogel gel (transdermal) 16.2 mg per g, 88 g delisted 1 April 2025.				
88	DESMOPRESSIN ACETATE (new listing and delisted) Nasal spray 10 mcg per dose, 6 ml – 5% DV Apr-25 to 2026	34.95	60	Desmopressin-PH&T
Note – Desmopressin-PH&T nasal spray 10 mcg per dose, 6 ml delisted 1 April 2025.				

INFECTIONS

90	CEFTAZIDIME WITH AVIBACTAM (new listing) → Inj ceftazidime 2,000 mg with avibactam 500 mg, vial.....	2,250.00	10	Zavicefta
Restricted Initiation Both				
1. Prescribed by, or recommended by a clinical microbiologist or infectious disease specialist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital; and				
2. Either:				
2.1. Proven infection with a carbapenem-resistant micro-organism, based on microbiology report; or				
2.2. Probable infection with a carbapenem-resistant micro-organism, based on assessment by a clinical microbiologist or infectious disease specialist.				
95	COLISTIN SULPHOMETHATE [COLESTIMETHATE] (delisting) → Inj 150 mg per ml, 1 ml vial	65.00	1	Colistin-Link
Note – Colistin-link inj 150 mg per ml, 1 ml vial to be delisted 1 June 2025.				

MUSCULOSKELETAL SYSTEM

113	ZOLEDRONIC ACID (new listing and delisted) Inj 5 mg per 100 ml, 100 ml bag – 5% DV Apr-25 to 2025	22.53	1	Zoledronic Acid Viatrix
Note – Zoledronic Acid Viatrix inj 5 mg per 100 ml, bag, 100 ml delisted 1 April 2025.				
118	DICLOFENAC SODIUM (↓ price and addition of PSS) Tab long-acting 75 mg – 5% DV Aug-25 to 2028	10.00	100	Voltaren SR

NERVOUS SYSTEM

122	BUPIVACAINE HYDROCHLORIDE (delisting) Inj 2.5 mg per ml, 100 ml bag	150.00	5	Marcaïn
Note – Marcaïn inj 2.5 mg per ml, 100 ml bag to be delisted 1 November 2025.				

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

135	QUETIAPINE (new listing)			
	Tab 25 mg.....	0.79	30	Quetiapine Viatris
		13.11	500	Quetiapine Viatris
145	METHYLPHENIDATE HYDROCHLORIDE (amended restriction criteria – new criteria shown only)			
	→ Tab extended-release 18 mg.....	58.96	30	Concerta
		7.75		Methylphenidate ER - Teva
	→ Tab extended-release 27 mg.....	65.44	30	Concerta
		11.45		Methylphenidate ER - Teva
	→ Tab extended-release 36 mg.....	71.93	30	Concerta
		15.50		Methylphenidate ER - Teva
	→ Tab extended-release 54 mg.....	86.24	30	Concerta
		22.25		Methylphenidate ER - Teva
	→ Tab immediate-release 5 mg.....	3.20	30	Rubifen
	→ Tab immediate-release 10 mg.....	4.00	30	Ritalin
		3.00		Rubifen
	→ Tab immediate-release 20 mg.....	7.85	30	Rubifen
	→ Tab sustained-release 20 mg.....	10.95	30	Rubifen SR
	→ Cap modified-release 10 mg.....	19.41	30	Ritalin LA
	→ Cap modified-release 20 mg.....	27.72	30	Ritalin LA
	→ Cap modified-release 30 mg.....	34.39	30	Ritalin LA
	→ Cap modified-release 40 mg.....	38.67	30	Ritalin LA

Restricted

Initiation – Narcolepsy* (extended-release only)

Neurologist or respiratory specialist

Patient suffers from narcolepsy

Note: *narcolepsy is not a registered indication for Concerta or Ritalin LA.

145	MODAFINIL (amended restriction criteria)			
	→ Tab 100 mg – 5% DV May-25 to 2027	14.27	30	Modafinil Max Health
		29.13	60	Modavigil

Restricted

Initiation – Narcolepsy

Neurologist or respiratory specialist

Either:

1 All of the following:

1.1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and

1.2 Either:

1.2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or

1.2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

1.3 Either:

1.3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialed and discontinued because of intolerable side effects; or

1.3.2 Methylphenidate and dexamphetamine are contraindicated; or

2 Both:

2.1 Patient meets the Hospital Restriction criteria for methylphenidate hydrochloride for narcolepsy; and

2.2 Patient is unable to access methylphenidate hydrochloride presentations due to an out of stock (see note).

Note – Criterion 2 is to permit short-term funding to cover an out-of-stock of methylphenidate hydrochloride.

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

147	VARENICLINE (new listing and delisted)			
	→ Tab 0.5 mg × 11 and 1 mg × 42.....	16.67	53	Champix
	→ Tab 1 mg.....	17.62	56	Champix

Note – Varenicline Pfizer tab 0.5 mg × 11 and 1 mg × 42 and tab 1 mg delisted on 1 April 2025.

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

160	AXITINIB (new listing)			
	→ Tab 1 mg.....	536.40	28	Intyla
	→ Tab 5 mg.....	2,682.00	28	Intyla

Restricted

Initiation

Re-assessment required after 4 months

All of the following:

1. The patient has metastatic renal cell carcinoma; and
2. The disease is of predominant clear cell histology; and
3. The patient has documented disease progression following one previous line of treatment; and
4. The patient has ECOG performance status of 0-2.

Continuation

Re-assessment required after 4 months

No evidence of disease progression.

160	CRIZOTINIB (new listing)			
	→ Cap 200 mg	7,250.00	60	Xalkori
	→ Cap 250 mg	7,250.00	60	Xalkori

Restricted

Initiation

Re-assessment required after 6 months

All of the following:

1. Patient has locally advanced or metastatic, unresectable, non-squamous non-small cell lung cancer; and
2. There is documentation confirming that the patient has a ROS1 rearrangement using an appropriate ROS1 test; and
3. Patient has ECOG performance score of 0-3; and
4. Baseline measurement of overall tumour burden is documented clinically and radiologically.

Continuation

Re-assessment required after 6 months

Both:

1. Response to treatment has been determined by comparable radiological assessment following the most recent treatment period; and
2. No evidence of disease progression.

165	RIBOCICLIB (new Pharmacode listings)			
	→ Tab 200 mg.....	1,883.00	21	Kisqali
		3,767.00	42	Kisqali
		5,650.00	63	Kisqali

Note – new Pharmacodes for Kisqali tab 200 mg are 21 pack 2701340, 42 pack 2701359 and 63 pack 2701367.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

165	RIBOCICLIB (delisting)			
	→ Tab 200 mg	1,883.00	21	Kisqali
		3,767.00	42	Kisqali
		5,650.00	63	Kisqali

Note – Pharmacodes 2678772, 2678780 and 2678799 respectively to be delisted 1 December 2025.

167	SUNITINIB (amended restriction criteria – affected criteria shown only)			
	→ Cap 12.5 mg	208.38	28	Sunitinib Pfizer
	→ Cap 25 mg	416.77	28	Sunitinib Pfizer
	→ Cap 50 mg	694.62	28	Sunitinib Pfizer

Restricted

Initiation – RCC

Re-assessment required after 3 4 months

All of the following–Both:

1 The patient has metastatic renal cell carcinoma of predominantly clear cell histology; and

2 **The patient has not previously received funded sunitinib.**

2– Any of the following:

2.1 The patient is treatment naive; or

2.2 The patient has only received prior cytokine treatment; or

2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or

2.4 Both:

2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and

2.4.2 The cancer did not progress whilst on pazopanib; and

3 The patient has an ECOG performance score of 0-2; and

4 Sunitinib to be used for a maximum of 2 cycles.

Continuation – RCC

Re-assessment required after 3 4 months

No evidence of disease progression.

168	CALCIUM FOLINATE (new listing)			
	Inj 10 mg per ml, 5 ml vial	112.20	5	Eurofolic
	Inj 10 mg per ml, 10 ml vial	163.35	5	Eurofolic

168	CALCIUM FOLINATE († price)			
	Inj 10 mg per ml, 100 ml vial	139.48	1	Eurofolic

168	CALCIUM FOLINATE (delisting)			
	Inj 10 mg per ml, 5 ml ampoule	18.25	5	Calcium Folate Ebewe
	Inj 10 mg per ml, 5 ml vial	7.28	1	Calcium Folate Sandoz
	Inj 10 mg per ml, 10 ml vial	9.49	1	Calcium Folate Sandoz
	Inj 10 mg per ml, 30 ml vial	22.51	1	Calcium Folate Ebewe
	Inj 10 mg per ml, 35 ml vial	25.14	1	Calcium Folate Sandoz
	Inj 10 mg per ml, 100 ml vial	72.00	1	Calcium Folate Sandoz

Note – Calcium Folate Ebewe inj 10 mg per ml, 5 ml ampoule, Calcium Folate Sandoz inj 10 mg per ml, 5 ml vial, inj 10 mg per ml, 10 ml vial and inj 10 mg per ml, 100 ml vial to be delisted 1 November 2025. Calcium Folate Ebewe inj 10 mg per ml, 30 ml vial and Calcium Folate Sandoz inj 10 mg per ml, 35 ml vial brand only to be delisted 1 November 2025.

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

171	LANREOTIDE (new listing) → Inj 90 mg per 0.5 ml, 0.5 ml syringe – 5% DV Sep-25 to 2027	562.92	1	Mytolac
172	TACROLIMUS (amended restriction criteria – affected criteria shown only) → Cap 0.5 mg → Cap 0.75 mg → Cap 1 mg → Cap 5 mg → Inj 5 mg per ml, 1 ml ampoule Restricted Initiation – organ transplant recipients Any specialist Either: 1 For use in organ transplant recipients; or 2 The individual is receiving induction therapy for an organ transplant	49.60 99.30 84.30 248.20	100 100 100 50	Tacrolimus Sandoz Tacrolimus Sandoz Tacrolimus Sandoz Tacrolimus Sandoz
198	BEVACIZUMAB (amended restriction criteria – affected criteria shown only) → Inj 25 mg per ml, 4 ml vial – 10% DV Aug-25 to 31 Aug 2028 → Inj 25 mg per ml, 16 ml vial – 10% DV Aug-25 to 31 Aug 2028	69.00 276.00	1 1	Vegzelma Vegzelma
	Restricted Initiation – advanced or metastatic ovarian cancer <i>Reassessment required after 4 months</i> All of the following: 1 Either: 1.1 The patient has FIGO Stage IV epithelial ovarian, fallopian tube or peritoneal cancer; or 1.2 Both: 1.2.1 The patient has previously untreated advanced (FIGO Stage IIIB or IIIC) epithelial ovarian, fallopian tube or peritoneal cancer; and 1.2.2 Either: 1.2.2.1 Debulking surgery is inappropriate; or 1.2.2.2 The cancer is sub-optimally debulked (maximum diameter of any gross residual disease greater than 1cm); and 2 Bevacizumab to be administered at a maximum dose of 7-5 15 mg/kg every three weeks; and 3 18 months concurrent treatment with chemotherapy is planned			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

200	IPILIMUMAB (new listing)			
	→ Inj 5 mg per ml, 10 ml vial	5,000.00	1	Yervoy
	→ Inj 5 mg per ml, 40 ml vial	20,000.00	1	Yervoy
	Restricted			
	Initiation – renal cell carcinoma			
	<i>Limited to 4 months treatment</i>			
	Either:			
	1. The patient is currently on treatment with ipilimumab and met all remaining criteria prior to commencing treatment; and			
	2. All of the following:			
	2.1. The patient has metastatic renal cell carcinoma; and			
	2.2. The patient is treatment naïve; and			
	2.3. The patient has ECOG performance status 0-2; and			
	2.4. The disease is predominant clear cell histology; and			
	2.5. Any of the following:			
	2.5.1. The patient has sarcomatoid histology; or			
	2.5.2. Haemoglobin levels less than the lower limit of normal; or			
	2.5.3. Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L); or			
	2.5.4. Neutrophils greater than the upper limit of normal; or			
	2.5.5. Platelets greater than the upper limit of normal; or			
	2.5.6. Interval of less than 1 year from original diagnosis to the start of systemic therapy; or			
	2.5.7. Karnofsky performance score of less than or equal to 70; and			
	2.6. Ipilimumab is to be used at a maximum dose of 1 mg/kg for up to four cycles in combination with nivolumab.			
200	INOTUZUMAB OZOGAMICIN (new listing)			
	→ Inj 1 mg vial.....	14,457.00	1	Besponsa
	Restricted			
	Initiation			
	<i>Re-assessment required after 4 months</i>			
	All of the following:			
	1. Patient has relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia/lymphoma, including minimal residual disease; and			
	2. Patient has ECOG performance status of 0-2; and			
	3. Either:			
	3.1. Both:			
	3.1.1. Patient has Philadelphia chromosome positive B-Cell ALL; and			
	3.1.2. Patient has previously received a tyrosine kinase inhibitor; or			
	3.2. Patient has received one prior line of treatment involving intensive chemotherapy; and			
	4. Treatment is to be administered for a maximum of 3 cycles.			
	Continuation			
	<i>Re-assessment required after 4 months</i>			
	1. Patient is not proceeding to a stem cell transplant; and			
	2. Either:			
	2.1 Patient has experienced complete disease response; or			
	2.2 Patient has experienced complete remission with incomplete haematological recovery; and			
	3. Treatment with inotuzumab ozogamicin is to cease after a total duration of 6 cycles.			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

244	NIVOLUMAB (amended restriction criteria – affected criteria shown only)		
	→ Inj 10 mg per ml, 4 ml vial	1,051.98	1 Opdivo
	→ Inj 10 mg per ml, 10 ml vial	2,629.96	1 Opdivo

Restricted

Initiation – renal cell carcinoma, **second line**

Relevant specialist or any relevant practitioner on the recommendation of a relevant specialist

Re-assessment required after 4 months

Either:

1. Patient is currently on treatment with nivolumab and met all remaining criteria prior to commencing treatment; or

2. All of the following:

2-1. 1. Patient has metastatic renal-cell carcinoma; and

2-2. 2. The disease is of predominant clear-cell histology; and

2-3. 3. Patient has an ECOG performance score of status 0-2; and

2-4. 4. Patient has documented disease progression following one or two previous regimens of antiangiogenic therapy; and

5. Patient has not previously received a funded immune checkpoint inhibitor; and

2-5. 6. Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression.

Initiation – renal cell carcinoma, **first line**

Reassessment required after 4 months

Either:

1. Patient is currently on treatment with nivolumab and met all remaining criteria prior to commencing treatment; or

2. All of the following:

2.1. The patient has metastatic renal cell carcinoma; and

2.2. The patient is treatment naïve; and

2.3. The patient has ECOG performance status 0-2; and

2.4. The disease is predominantly of clear cell histology; and

2.5. Any of the following:

2.5.1. The patient has sarcomatoid histology; or

2.5.2. Haemoglobin levels less than the lower limit of normal; or

2.5.3. Corrected serum calcium level greater than 10 mg/dL (2.5 mmol/L); or

2.5.4. Neutrophils greater than the upper limit of normal; or

2.5.5. Platelets greater than the upper limit of normal; or

2.5.6. Interval of less than 1 year from original diagnosis to the start of systemic therapy; or

2.5.7. Karnofsky performance score of less than or equal to 70; and

2.6. Nivolumab is to be used in combination with ipilimumab for the first four treatment cycles at a maximum dose of 3 mg/kg; and

2.7. Nivolumab is to be used at a maximum maintenance dose of 240 mg every 2 weeks (or equivalent).

Continuation – renal cell carcinoma

Any relevant practitioner

Reassessment required after 4 months

All of the following:

1. Any of the following:

1.1. Patient's disease has had a complete response to treatment; or

1.2. Patient's disease has had a partial response to treatment; or

1.3. Patient has stable disease; and

2. No evidence of disease progression; and

3. Nivolumab is to be used as monotherapy at a maximum dose of 240 mg every 2 weeks (or equivalent) and discontinued at disease progression.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

264 ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAFTOR (amended restriction criteria)

→ Tab elexacaftor 50 mg with tezacaftor 25 mg, ivacaftor 37.5 mg (56) and ivacaftor 75 mg (28)	27,647.39	84	Trikafta
→ Tab elexacaftor 100 mg with tezacaftor 50 mg, ivacaftor 75 mg (56) and ivacaftor 150 mg (28)	27,647.39	84	Trikafta

Restricted
Initiation

All of the following:

1 Patient has been diagnosed with cystic fibrosis; and

2 Patient is 6 years of age or older; and

3 Either:

3.1 Patient has two cystic fibrosis-causing mutations in the cystic fibrosis transmembrane regulator (CFTR) gene (one from each parental allele); or

3.2 Patient has a sweat chloride value of at least 60 mmol/L by quantitative pilocarpine iontophoresis or by Macroduct sweat collection system; and

4 Either:

4.1 Patient has a heterozygous or homozygous F508del mutation; or

4.2 Patient has a G551D mutation or other mutation responsive in vitro to elexacaftor/tezacaftor/ivacaftor (see note a); and

5 The treatment must be the sole funded CFTR modulator therapy for this condition; and

6 Treatment with elexacaftor/tezacaftor/ivacaftor must be given concomitantly with standard therapy for this condition.

Notes:

a) Eligible mutations are listed in the Food and Drug Administration (FDA) Trikafta prescribing information

<https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/f354423a-85c2-41c3-a9db-0f3aee135d8d/spl-doc>

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004tbl.pdf

SENSORY ORGANS

270 ACETAZOLAMIDE (new listing and addition of PSS)

Tab 250 mg – 5% DV Sep 25 to 2027	13.96	100	Medsurge
--	-------	-----	-----------------

Note – Diamox tab 250 mg to be delisted on 1 September 2025.

VARIOUS

273 ACETYLCYSTEINE (new listing)

Inj 200 mg per ml, 10 ml vial	42.99	10	Hikma Acetylcysteine
-------------------------------------	-------	----	----------------------

277 GADOBUTROL (new listing)

Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 65 ml bottle.....	3,120.00	10	Gadovist 1.0
--	----------	----	--------------

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

SPECIAL FOODS

288	AMINO ACID FORMULA (WITHOUT PHENYLALANINE) (new listing and delisted) → Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle.....	13.10	1	PKU Anamix Junior LQ (Berry) PKU Anamix Junior LQ (Orange)
	→ Powder (Neutral), 14.3 g protein, 25 g fat per 100 g, 4 x 400 g can.....	715.16	1,600 g	PKU Start
	Note – PKU Anamix Junior LQ (Berry) and (Orange) liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle, 125 ml and PKU Start powder (Neutral), 14.3 g protein, 25 g fat per 100 g, 400 g can delisted 1 April 2025.			
291	DIABETIC ORAL FEED 1 KCAL/ML (new listing and delisted) → Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle	2.25	1	Diasip (strawberry) Diasip (vanilla)
	Note – Diasip (strawberry) and (vanilla) liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, bottle, 200 ml delisted 1 April 2025.			
291	LOW-GI ENTERAL FEED 1 KCAL/ML (new listing and delisted) → Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 500 ml bottle	4.65	1	Glucerna Select
	Note – Glucerna Select liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 500 ml bottle, 500 ml delisted 1 April 2025.			
291	LOW-GI ORAL FEED 1 KCAL/ML (new listing and delisted) → Liquid 7 g protein, 10.9 g carbohydrate, 2.7 g fat and 2 g fibre per 100 ml, 200 ml bottle	2.10	1	Nutren Diabetes (vanilla)
	Note – Nutren Diabetes (Vanilla) Liquid 7 g protein, 10.9 g carbohydrate, 2.7 g fat and 2 g fibre per 100 ml, bottle, 200 ml delisted 1 April 2025.			
292	AMINO ACID ORAL FEED (new listing and delisted) → Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet, 80 g sachet.....	4.50	1	Vivonex TEN
	Note – Vivonex TEN powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet, 80 g delisted 1 April 2025.			
292	PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML (new listing and delisted) → Liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, 500 ml bottle.....	7.47	1	Nutrison Advanced Peptisorb
	Note – Nutrison Advanced Peptisorb liquid 4 g protein, 17.7 g carbohydrate and 1.7 g fat per 100 ml, bottle, 500 ml delisted 1 April 2025.			
292	PEPTIDE-BASED ENTERAL FEED 1.5 KCAL/ML (new listing and delisted) → Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, 1,000 ml bottle.....	22.39	1	Vital
	Note – Vital liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle, 1,000 ml delisted 1 April 2025.			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

293	<p>ENTERAL FEED 2 KCAL/ML (new listing and delisted)</p> <p>→ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 500 ml bottle 6.82 1 Nutrison Concentrated</p> <p>→ Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, 1,000 ml bottle 13.64 1 Ensure Two Cal HN RTH</p> <p>Note – Nutrison Concentrated liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle, 500 ml and Ensure Two Cal HN RTH liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle, 1,000 ml delisted 1 April 2025.</p>
293	<p>ORAL FEED 2 KCAL/ML (new listing and delisted)</p> <p>→ Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, 200 ml bottle 2.34 1 Two Cal HN</p> <p>Note – Two Cal HN liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle, 200 ml delisted 1 April 2025.</p>
295	<p>ENTERAL LIQUID PEPTIDE FORMULA (new listing and delisted)</p> <p>→ Liquid 4.2 g protein, 18.6 g carbohydrate and 6.58 g fat per 100 ml, 500 ml bottle 18.66 1 Nutrini Peptisorb Energy</p> <p>Note – Nutrini Peptisorb Energy liquid 4.2 g protein, 18.6 g carbohydrate and 6.58 g fat per 100 ml, 500 ml delisted 1 April 2025.</p>
296	<p>PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML (new listing and delisted)</p> <p>→ Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, 125 ml bottle 2.80 1 Infatrini</p> <p>Note – Infatrini liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, bottle, 125 ml delisted 1 April 2025.</p>
297	<p>PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML (new listing and delisted)</p> <p>→ Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, 500 ml bottle 6.27 1 bag Nutrini Low Energy Multifibre RTH</p> <p>Note – Nutrini Low Energy Multifibre RTH liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag, 500 ml delisted 1 April 2025.</p>
298	<p>PAEDIATRIC ENTERAL FEED 1 KCAL/ML (new listing and delisted)</p> <p>→ Liquid 2.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bottle 4.69 1 Nutrini RTH</p> <p>→ Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 500 ml bottle 3.32 1 PediaSure RTH</p> <p>Note – Nutrini RTH liquid 2.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, bottle, 500 ml and PediaSure RTH liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag, 500 ml delisted 1 April 2025.</p>
298	<p>PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML (new listing and delisted)</p> <p>→ Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bottle 7.46 1 Nutrini Energy RTH</p> <p>→ Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, 500 ml bottle 7.14 1 Nutrini Energy Multi Fibre</p> <p>Note – Nutrini Energy RTH liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, bottle, 500 ml and Nutrini Energy Multi Fibre liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bottle, 500 ml delisted 1 April 2025.</p>

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

298	PAEDIATRIC ORAL FEED 1 KCAL/ML (new listing and delisted)		
	→ Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 200 ml bottle	1.33	1 Pediasure (chocolate) Pediasure (strawberry) Pediasure (vanilla)
	→ Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 250 ml can	1.66	1 Pediasure (vanilla)
	Note – Pediasure (Chocolate), (Strawberry) and (Vanilla) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bottle, 200 ml and Pediasure (Vanilla) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, can, 200 ml delisted 1 April 2025.		
298	PAEDIATRIC ORAL FEED 1.5 KCAL/ML (new listing and delisted)		
	→ Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle	1.90	1 Fortini (Strawberry) Fortini (Vanilla)
	→ Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle	1.90	1 Fortini Multi Fibre (chocolate) Fortini Multi Fibre (strawberry) Fortini Multi Fibre (unflavoured) Fortini Multi Fibre (vanilla)
	→ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle	8.67	1 Pediasure Plus
	Note – Fortini (Strawberry) and (Vanilla) liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, bottle, 200 ml; Fortini Multi Fibre (Chocolate), (Strawberry), (Unflavoured) and (Vanilla) liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, bottle, 200 ml and Pediasure Plus liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle, 500 ml delisted 1 April 2025.		
298	LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML (new listing and delisted)		
	→ Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, 220 ml carton.....	3.31	1 Nepro HP (Strawberry) Nepro HP (Vanilla)
	Note – Nepro HP (Strawberry) and (Vanilla) liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton, 220 ml delisted 1 April 2025.		
299	ENTERAL FEED 1.5 KCAL/ML (new listing and delisted)		
	→ Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, 1,000 ml bottle	9.00	1 Nutrison Energy
	→ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle	8.68	1 Nutrison Energy Multi Fibre
	→ Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, 250 ml can	2.17	1 Ensure Plus HN
	→ Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bag	8.68	1 Ensure Plus HN RTH
	→ Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, 1,000 ml bag	8.68	1 Jevity HiCal RTH
	Note – Nutrison Energy liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bottle, 1,000 ml; Nutrison Energy Multi Fibre liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, bottle, 1,000 ml; Ensure Plus HN liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can, 250 ml; Ensure Plus HN RTH liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag, 1,000 ml and Jevity HiCal RTH liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag, 1,000 ml delisted 1 April 2025.		

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

299	ENTERAL FEED 1 KCAL/ML (new listing and delisted)		
	→ Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bottle	6.90	1 Nutrison RTH
	→ Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle	7.21	1 Nutrison Multi Fibre
	→ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, 1,000 ml bottle	6.56	1 Osmolite RTH
	→ Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, 1,000 ml bottle	6.56	1 Jevity RTH
	Note – Nutrison RTH liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, bottle, 1,000 ml; Nutrison Multi Fibre liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, bottle, 1,000 ml; Osmolite RTH liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle, 1,000 ml; Jevity RTH liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle, 1,000 ml delisted 1 April 2025.		
300	ENTERAL FEED 1.2 KCAL/ML (new listing and delisted)		
	→ Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bottle	7.87	1 Jevity Plus RTH
	Note – Jevity Plus RTH liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag, 1,000 ml delisted 1 April 2025.		
300	ENTERAL FEED WITH FIBRE 0.83 KCAL/ML (new listing and delisted)		
	→ Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, 1,000 ml bottle	9.05	1 Nutrison 800 Complete Multi Fibre
	Note – Nutrison 800 Complete Multi Fibre liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, bottle, 1,000 ml delisted 1 April 2025.		
300	ORAL FEED 1.5 KCAL/ML (new listing and delisted)		
	→ Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, 237 ml can	1.65	1 Ensure Plus (Vanilla)
	→ Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle	1.76	1 Fortisip (banana) Fortisip (chocolate) Fortisip (strawberry) Fortisip (vanilla)
	→ Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, 200 ml bottle	1.56	1 Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla)
	Note – Ensure Plus (Vanilla) liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can, 237 ml; Fortisip (banana), (chocolate), (strawberry) and (vanilla) liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle, 200 ml and Ensure Plus (Banana), (Chocolate), (Fruit of the Forest) and (Vanilla) liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, bottle, 200 ml delisted 1 April 2025.		
301	ORAL FEED WITH FIBRE 1.5 KCAL/ML (new listing and delisted)		
	→ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle	1.76	1 Fortisip Multi Fibre (chocolate) Fortisip Multi Fibre (strawberry) Fortisip Multi Fibre (vanilla)
	Note – Fortisip Multi Fibre (chocolate), (strawberry) and (vanilla) liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle, 200 ml delisted 1 April 2025.		

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 April 2025 (continued)

VACCINES

310	ROTAVIRUS ORAL VACCINE (new listing) → Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose, squeezable tube (PVC free)	0.00	10	Rotarix
-----	--	------	----	---------

Index

Pharmaceuticals and brands

A	
ACETAZOLAMIDE.....	18
ACETYLCYSTEINE.....	18
AMINO ACID FORMULA (WITHOUT PHENYLALANINE).....	19
AMINO ACID ORAL FEED.....	19
APO Health Macrogol.....	10
AXITINIB.....	13
B	
Besponsa.....	16
BEVACIZUMAB.....	15
BUPIVACAINE HYDROCHLORIDE.....	11
C	
CALCITRIOL.....	10
Calcitriol AFT.....	10
Calcitriol XL.....	10
CALCIUM FOLINATE.....	14
Calcium Folate Ebewe.....	14
Calcium Folate Sandoz.....	14
CEFTAZIDIME WITH AVIBACTAM.....	11
Cerazette.....	10
CETOMACROGOL WITH GLYCEROL.....	10
Champix.....	13
COLESTIMETHATE.....	11
Colistin-Link.....	11
COLISTIN SULPHOMETHATE [COLESTIMETHATE].....	11
COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE].....	10
Concerta.....	12
CRIZOTINIB.....	13
D	
DESMOPRESSIN ACETATE.....	11
Desmopressin-PH&T.....	11
DESOGESTREL.....	10
DEXTROSE.....	10
DIABETIC ORAL FEED 1 KCAL/ML.....	19
Diasip (strawberry).....	19
Diasip (vanilla).....	19
DICLOFENAC SODIUM.....	11
DIMETHICONE.....	10
E	
ELEXACAFTOR WITH TEZACAFTOR, IVACAFTOR AND IVACAFTOR.....	18
Ensure Plus (Banana).....	22
Ensure Plus (Chocolate).....	22
Ensure Plus (Fruit of the Forest).....	22
Ensure Plus HN.....	21
Ensure Plus HN RTH.....	21
Ensure Plus (Vanilla).....	22
Ensure Two Cal HN RTH.....	20
ENTERAL FEED 1.2 KCAL/ML.....	22
ENTERAL FEED 1.5 KCAL/ML.....	21
ENTERAL FEED 1 KCAL/ML.....	22
ENTERAL FEED 2 KCAL/ML.....	20
ENTERAL FEED WITH FIBRE 0.83 KCAL/ML.....	22
ENTERAL LIQUID PEPTIDE FORMULA.....	20
Eurofolic.....	14
F	
Fortini Multi Fibre (chocolate).....	21
Fortini Multi Fibre (strawberry).....	21
Fortini Multi Fibre (unflavoured).....	21
Fortini Multi Fibre (vanilla).....	21
Fortini (Strawberry).....	21
Fortini (Vanilla).....	21
Fortisip (banana).....	22
Fortisip (chocolate).....	22
Fortisip Multi Fibre (chocolate).....	22
Fortisip Multi Fibre (strawberry).....	22
Fortisip Multi Fibre (vanilla).....	22
Fortisip (strawberry).....	22
Fortisip (vanilla).....	22
G	
GADOBUTROL.....	18
Gadovist 1.0.....	18
Glucerna Select.....	19
H	
healthE Dimethicone 5%.....	10
healthE Dimethicone 10%.....	10
Hikma Acetylcysteine.....	18
Hydralyte – Lemonade.....	10
I	
Infatrin.....	20
INOTUZUMAB OZOGAMICIN.....	16
Intyla.....	13
IPILIMUMAB.....	16
J	
Jadelle.....	11
Jevity HiCal RTH.....	21
Jevity Plus RTH.....	22
Jevity RTH.....	22
K	
Kisqali.....	13, 14
L	
LANREOTIDE.....	15
LEVONORGESTREL.....	11
LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML.....	21
LOW-GI ENTERAL FEED 1 KCAL/ML.....	19
LOW-GI ORAL FEED 1 KCAL/ML.....	19
M	
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE..	10

Index

Pharmaceuticals and brands

Marcaïn	11	PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML	19
Methylphenidate ER - Teva	12	PKU Anamix Junior LQ (Berry).....	19
METHYLPHENIDATE HYDROCHLORIDE.....	12	PKU Anamix Junior LQ (Orange).....	19
MODAFINIL	12	PKU Start	19
Modafinil Max Health.....	12	Q	
Modavigil	12	QUETIAPINE.....	12
Mytolac.....	15	Quetiapine Viatrix	12
N		R	
Nepro HP (Strawberry)	21	RIBOCICLIB	13, 14
Nepro HP (Vanilla).....	21	Ritalin	12
NIVOLUMAB	17	Ritalin LA	12
Nutren Diabetes (vanilla)	19	Rotarix.....	23
Nutrini Energy Multi Fibre.....	20	ROTAVIRUS ORAL VACCINE	23
Nutrini Energy RTH.....	20	Rubifen	12
Nutrini Low Energy Multifibre RTH	20	Rubifen SR	12
Nutrini Peptisorb Energy	20	S	
Nutrini RTH	20	SUNITINIB.....	14
Nutrison 800 Complete Multi Fibre.....	22	Sunitinib Pfizer	14
Nutrison Advanced Peptisorb	19	T	
Nutrison Concentrated.....	20	TACROLIMUS	15
Nutrison Energy	21	Tacrolimus Sandoz	15
Nutrison Energy Multi Fibre.....	21	Testogel.....	11
Nutrison Multi Fibre	22	TESTOSTERONE	11
Nutrison RTH	22	THIAMINE HYDROCHLORIDE	10
O		Trikafta	18
Opdivo	17	Two Cal HN.....	20
ORAL FEED 1.5 KCAL/ML	22	U	
ORAL FEED 2 KCAL/ML	20	URSODEOXYCHOLIC ACID	10
ORAL FEED WITH FIBRE 1.5 KCAL/ML	22	Ursosan.....	10
Osmolite RTH.....	22	V	
P		VARENICLINE	13
PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML	20	Vegzelma	15
PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML	20	Vital	19
PAEDIATRIC ENTERAL FEED 1 KCAL/ML	20	Vivonex TEN.....	19
PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML	20	Voltaren SR.....	11
PAEDIATRIC ORAL FEED 1.5 KCAL/ML	21	X	
PAEDIATRIC ORAL FEED 1 KCAL/ML	21	Xalkori	13
Pediasure (chocolate)	21	Y	
Pediasure Plus	21	Yervoy	16
Pediasure RTH.....	20	Z	
Pediasure (strawberry).....	21	Zavicefta	11
Pediasure (vanilla).....	21	ZOLEDRONIC ACID	11
PEPTIDE-BASED ENTERAL FEED 1.5 KCAL/ML	19	Zoledronic Acid Viatrix.....	11

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

